Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

ITCI Company Profile and Key Details

NASDAQ : ITCI

Intra-Cellular Therapies, Inc.

$131.87
00
Open: 4:00 PM
Not Actively Trading
67.83
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Intra-Cellular Therapies, Inc. (ITCI) stock remained unchanged at $131.87 a share on NASDAQ. The stock opened at $131.87, fluctuating between $131.87 to $131.87 during the session.

Stock Snapshot

131.87
Prev. Close
14.05B
Market Cap
131.87
Day Low
-180.64
P/E Ratio
-0.73
EPS (TTM)
-1.29
Cash Flow per Share
131.87
Open
106.52M
Number of Shares
131.87
Day High
98.4%
Free Float in %
6.14
Book Value
16.04M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Apr 01, 2025131.90131.98131.63131.8715.53M
Mar 31, 2025131.84131.95131.80131.922.55M
Mar 28, 2025131.85131.87131.79131.811.58M
Mar 27, 2025131.75131.79131.71131.751.87M
Mar 26, 2025131.78131.78131.65131.691.02M
Mar 25, 2025131.75131.79131.63131.701.13M
Mar 24, 2025131.58131.71131.58131.70661.02K
Mar 21, 2025131.55131.67131.51131.651.84M
Mar 20, 2025131.55131.60131.50131.60921.9K
Mar 19, 2025131.45131.57131.45131.531.23M
Mar 18, 2025131.42131.48131.35131.451.47M
Mar 17, 2025131.29131.46131.27131.45996.8K
Mar 14, 2025131.28131.40131.24131.261.5M
Mar 13, 2025131.24131.37131.22131.361.8M
Mar 12, 2025131.25131.33131.19131.252.68M
Mar 11, 2025131.24131.37131.23131.243.74M
Mar 10, 2025131.21131.28131.20131.252.62M
Mar 07, 2025131.30131.32131.21131.241.26M
Mar 06, 2025131.23131.28131.20131.251.16M
Mar 05, 2025131.28131.35131.18131.192.87M

Contact Details

New York, NY 10016

United States

https://www.intracellulartherapies.com646 440 9333

About Company

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Company Information

Employees860
Beta0.46
Sales or Revenue$462.18M
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Frequently Asked Questions

What is the current Intra-Cellular Therapies, Inc. (ITCI) stock price?
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) stock price is $131.87 in the last trading session. During the trading session, ITCI stock reached the peak price of $131.87 while $131.87 was the lowest point it dropped to. The percentage change in ITCI stock occurred in the recent session was 0% while the dollar amount for the price change in ITCI stock was -.
ITCI's industry and sector of operation?
The NASDAQ listed ITCI is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Intra-Cellular Therapies, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ITCI?
Dr. Robert E. Davis Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Karen Patruno Sheehy Esq.
Senior Vice President & Chief Compliance Officer
Dr. Michael Olchaskey
Senior Vice President & Head of Regulatory Affairs
Mr. Mark Neumann
EVice President & Chief Commercial Officer
Mr. Juan Fernando Sanchez
Vice President of Corporation Communications & Investor Relations
Mr. Lawrence J. Hineline CPA, CPA
Senior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec.
Mr. John A. Bardi
Senior Vice President of Market Access, Policy & Gov. Affairs
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman, Chief Executive Officer & Pres
Mr. Michael I. Halstead J.D.
Executive Vice President, Gen. Counsel & Sec.
Dr. Suresh K. Durgam M.D.
Executive Vice President & Chief Medical Officer
How ITCI did perform over past 52-week?
ITCI's closing price is 105.76% higher than its 52-week low of $64.09 where as its distance from 52-week high of $131.98 is -0.08%.
How many employees does ITCI have?
Number of ITCI employees currently stands at 860.
Link for ITCI official website?
Official Website of ITCI is: https://www.intracellulartherapies.com
How do I contact ITCI?
ITCI could be contacted at phone 646 440 9333 and can also be accessed through its website. ITCI operates from 430 East 29th Street, New York, NY 10016, United States.
How many shares of ITCI are traded daily?
ITCI stock volume for the day was 16.04M shares. The average number of ITCI shares traded daily for last 3 months was 3.62M.
What is the market cap of ITCI currently?
The market value of ITCI currently stands at $14.05B with its latest stock price at $131.87 and 106.52M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings Calendar
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph